{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:14:40Z","timestamp":1792512880820,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.schres.2017.08.027","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T11:45:30Z","timestamp":1503575130000},"page":"275-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study"],"prefix":"10.1016","volume":"195","author":[{"given":"Brian J.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2017.08.027_bb0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/adb.12156","article-title":"Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatients treatment: influence of cocaine symptom severity and psychiatric co-morbidity","volume":"20","author":"Araos","year":"2015","journal-title":"Addict. Biol."},{"key":"10.1016\/j.schres.2017.08.027_bb0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1176\/appi.ajp.2013.13010086","article-title":"A Nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis","volume":"171","author":"Benros","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/appi.ajp.2009.09030361","article-title":"Prenatal infection and schizophrenia: a review of epidemiologic and translational studies","volume":"167","author":"Brown","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12888-016-0866-x","article-title":"The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia","volume":"16","author":"Chase","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0025","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/appi.ajp.2009.08010031","article-title":"Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia","volume":"166","author":"Clarke","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2013.10.019","article-title":"Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway","volume":"151","author":"Dimitrov","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.08.027_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pnpbp.2013.06.011","article-title":"Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers","volume":"46","author":"Fernandez-Egea","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2015.11.017","article-title":"Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set","volume":"19","author":"Fond","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.schres.2017.08.027_bb0045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hup.1251","article-title":"Immune system inflammation in cocaine dependent individual: implications for medication development","volume":"27","author":"Fox","year":"2012","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2017.08.027_bb0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF02900219","article-title":"Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission","volume":"247","author":"Frommberger","year":"1997","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.schres.2017.08.027_bb0055","first-page":"449","article-title":"Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation","volume":"262","author":"Frydecka","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2017.08.027_bb0060","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1471-4159.2009.06325.x","article-title":"Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications","volume":"111","author":"Gaspar","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2017.08.027_bb0065","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"Meta-analysis of cytokine alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.08.027_bb0070","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1210\/jc.2002-020804","article-title":"DiminishedInterleukin-6 response to proinflammatory challenge in men and women after intravenous cocaine administration","volume":"88","author":"Halpern","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.schres.2017.08.027_bb0075","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.pnpbp.2011.05.011","article-title":"Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders","volume":"35","author":"Igue","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1124\/jpet.106.112797","article-title":"Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms","volume":"320","author":"Irwin","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.schres.2017.08.027_bb0085","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2017.08.027_bb0090","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1017\/S1355617714000691","article-title":"Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults","volume":"20","author":"Keen","year":"2014","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.schres.2017.08.027_bb0095","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1017\/S1355617714000691","article-title":"Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults","volume":"20","author":"Keen","year":"2015","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.schres.2017.08.027_bb0100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.drugalcdep.2014.04.011","article-title":"Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans","volume":"140","author":"Keen","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.schres.2017.08.027_bb0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2016.06.023","article-title":"Plasma interleukin-6 and executive function in crack cocaine-dependent women","volume":"628","author":"Levandowski","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2017.08.027_bb2015","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2017.08.027_bb0115","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1177\/1535370214537747","article-title":"System-levels view of cocaine addiction: the interconnection of the immune and nervous systems","volume":"239","author":"Marasco","year":"2014","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.schres.2017.08.027_bb0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-003-1750-1","article-title":"Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia","volume":"174","author":"Martin","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2017.08.027_bb0125","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/npp.2016.211","article-title":"Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future direction","volume":"42","author":"Miller","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2017.08.027_bb0135","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.08.027_bb0140","first-page":"S242","article-title":"Interleukin-6 and cognition in non-affective psychosis","volume":"39","author":"Miller","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.08.027_bb0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2015.10.001","article-title":"Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"169","author":"Mori","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.08.027_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00406-004-0478-1","article-title":"COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy","volume":"254","author":"Muller","year":"2004","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2017.08.027_bb0155","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.08.027_bb0160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbi.2009.04.005","article-title":"To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers","volume":"23","author":"O'Connor","year":"2009","journal-title":"Brain Behav. Immun."},{"issue":"15","key":"10.1016\/j.schres.2017.08.027_bb0165","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.289.15.1929-a","article-title":"Modulation of the immune system in Cannabis users","volume":"289","author":"Pacifi","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2017.08.027_bb0170","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.intimp.2005.10.004","article-title":"Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines","volume":"6","author":"Pae","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.schres.2017.08.027_bb0175","first-page":"1","article-title":"Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings","volume":"6","author":"Pedraz","year":"2015","journal-title":"Front. Psych."},{"issue":"1","key":"10.1016\/j.schres.2017.08.027_bb0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/13651501.2012.687452","article-title":"Factors associated with relapse in patients with schizophrenia","volume":"17","author":"San","year":"2013","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.schres.2017.08.027_bb0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","journal-title":"Nature"},{"issue":"7589","key":"10.1016\/j.schres.2017.08.027_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.schres.2017.08.027_bb0195","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nature08192","article-title":"Common variants on chromosome 6p22.1 are associated with schizophrenia","volume":"460","author":"Shi","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.schres.2017.08.027_bb0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.08.027_bb0205","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbi.2014.01.018","article-title":"Immune system: a possible nexus between cannabinoid and psychosis","volume":"40","author":"Suarez-Pinilla","year":"2014","journal-title":"Brain Behav. Immun."},{"issue":"1\u20132","key":"10.1016\/j.schres.2017.08.027_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-9964(95)00068-2","article-title":"Substance use: a powerful predictor of relapse in schizophrenia","volume":"20","author":"Swofford","year":"1996","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.08.027_bb0215","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2012.01.016","article-title":"Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study","volume":"137","author":"van Dijk","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.08.027_bb0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0006-8993(94)90006-X","article-title":"Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6","volume":"643","author":"Zalcman","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2017.08.027_bb0225","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0006-8993(99)02063-6","article-title":"Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats","volume":"847","author":"Zalcman","year":"1999","journal-title":"Brain Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417305030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417305030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:35:29Z","timestamp":1570030529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417305030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":46,"alternative-id":["S0920996417305030"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.08.027","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}